See the DrugPatentWatch profile for gilenya
What Gilenya Treats
Gilenya (fingolimod) is approved to treat relapsing forms of multiple sclerosis (MS) in adults and children aged 10 years and older. It reduces the frequency of clinical exacerbations and delays disability progression in patients with relapsing-remitting MS (RRMS), clinically isolated syndrome, or active secondary progressive MS.[1]
How Gilenya Works in MS
Gilenya traps certain white blood cells (lymphocytes) in lymph nodes, preventing them from entering the brain and spinal cord to cause inflammation and damage. This sphingosine 1-phosphate receptor modulator lowers relapse rates by about 50% compared to interferon beta-1a in clinical trials.[1][2]
Who Qualifies for Gilenya
It's indicated for patients with relapsing MS who have had at least one attack and show MRI evidence of brain lesions. Pediatric approval came in 2018 based on a trial showing similar efficacy and safety in kids aged 10-17.[1]
Common Side Effects Patients Report
Headache, back pain, high blood pressure, elevated liver enzymes, and infections top the list. Serious risks include slowed heart rate (first-dose monitoring required), macular edema, and progressive multifocal leukoencephalopathy (PML). It's not for those with heart conditions, active infections, or basal cell carcinoma history.[1][2]
How Gilenya Compares to Other MS Drugs
Unlike injectables like Avonex or Copaxone, Gilenya is an oral capsule taken once daily (0.5 mg for adults, 0.25 mg for kids). It outperforms placebo and some interferons in reducing relapses but has a black-box warning for infections and heart effects, unlike Tecfidera, which focuses on oral anti-inflammatory action.[2]
When Does Gilenya's Patent Expire
The main composition-of-matter patent (U.S. Patent No. 6,977,084) expires in November 2019, but method-of-use patents and pediatric exclusivity extend protection. Generic fingolimod entered the U.S. market in 2024 after FDA approval of challengers like Hikma's version. Check DrugPatentWatch.com for latest litigation and Paragraph IV challenges.[3]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022527s030lbl.pdf
[2] National MS Society: https://www.nationalmssociety.org/Treating-MS/Medications/Gilenya
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/GILENYA